Stealth mRNA nanovaccines to control lymph node trafficking
Author
Other authors
Publication date
2024-08-22ISSN
1873-4995
Abstract
mRNA-based vaccines symbolize a new paradigm shift in personalized medicine for the treatment of infectious and non-infectious diseases. However, the reactogenicity associated with the currently approved formulations limits their applicability in autoinflammatory disorders, such as tumour therapeutics. In this study, we present a delivery system showing controlled immunogenicity and minimal non-specific inflammation, allowing for selective delivery of mRNA to antigen presenting cells (APCs) within the medullary region of the lymph nodes. Our platform offers precise control over the trafficking of nanoparticles within the lymph nodes by optimizing stealth and targeting properties, as well as the subsequent opsonization process. By targeting specific cells, we observed a potent adaptive and humoral immune response, which holds promise for preventive and therapeutic anti-tumoral vaccines. Through spatial programming of nanoparticle distribution, we can promote robust immunization, thus improving and expanding the utilization of mRNA vaccines. This innovative approach signifies a remarkable step forward in the field of targeted nanomedicine.
Document Type
Article
Document version
Published version
Language
English
Subject (CDU)
539 - Physical nature of matter
Keywords
zwitterionics
mRNA
Nanoparticles
Delivery systems
cancer
Reactogenicity
Pages
12 p.
Publisher
Elsevier
Is part of
Journal of Controlled Release. 2024;374:325-336
Grant agreement number
info:eu-repo/grantAgreement/ISCIII/PN I+D/AC22/00042
info:eu-repo/grantAgreement/MICIN i FEDER/Proyecto PID2021-125910OB-I00
info:eu-repo/grantAgreement/SUR del DEC/SGR/2021 SGR 00537
This item appears in the following Collection(s)
Rights
© L'autor/a
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/